Mr. Eli Ben-Haroosh reports

ZERO CANDIDA ANNOUNCED OFFICIALLY BEEN GRANTED PATENT NO. 12654025B2 -- A MEANINGFUL MILESTONE THAT REFLECTS OUR COMMITMENT TO INNOVATION, TECHNOLOGY, AND LONG-TERM IMPACT

Zero Candida Technologies Inc. has been granted a new patent, No. 12654025B2, a meaningful milestone that reflects the company's commitment to innovation, technology and long-term impact.

Obtaining the patent is an important asset for the company and its unique technology.

Zero Candida sees the device as both a therapeutic and a gynecological device for the next century.

The device will be able to develop AI (artificial intelligence) capabilities that will both treat vaginal fungus infections and detect new diseases, also to report directly to the doctor, and order medication directly from the pharmacy.

ZC-001 is a smart, AI-enabled therapeutic device integrating precision blue light therapy, targeted drug delivery and wireless diagnostics for personalized at-home treatment of Vulvovaginal candidiasis (VVC). The device is designed to improve outcomes in recurrent and drug-resistant infections while reducing the need for repeated in-clinic visits. Its underlying technology may support future applications across other areas of women's health.

About Zero Candida Technologies Inc.

Zero Candida Technologies is a publicly traded femtech company pioneering innovative solutions to address unmet needs in women's health. The company is developing a smart, tampon-like device that combines artificial intelligence and therapeutic blue light at a precise wavelength and intensity to effectively treat VVC through personalized, at-home care. This condition affects approximately 75 per cent of women worldwide and recurrent cases (four or more episodes per year) are increasingly resistant to existing drug treatments, as the root cause remains poorly understood and inadequately addressed. With the VVC treatment market projected to exceed $2-billion (U.S.) by 2030, Zero Candida is combining hybrid medicine and technology-based diagnostics to improve access for underserved populations and bring gynecology into the 21st century.

We seek Safe Harbor.